{"title":"Home OCT and Sustained Delivery Approaches, a Perfect Marriage: Home OCT and Sustained Drug Delivery: A Perfect Marriage.","authors":"Nancy M Holekamp","doi":"10.1016/j.ajo.2024.10.031","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To provide a perspective on the management of neovascular age-related macular degeneration (nAMD) patients using a combination of sustained drug delivery strategies and remote monitoring technology.</p><p><strong>Design: </strong>Evidence-based perspective METHODS: Review of the literature and experience of the author RESULTS: Currently there are many ongoing research efforts in the retina field directed at both safe, effective sustained drug delivery and validated remote monitoring. At present, the Port Delivery System with ranibizumab and the Home OCT are FDA approved and available for use by clinicians. A review of available data and a case example demonstrate the potential for these combined technologies to reduce both the injection burden and the monitoring burden currently experienced by nAMD patients. Other sustained drug delivery strategies such as tyrorinse kinase inhibitor delivery systems and viral vector mediated anti-VEGF intraocular bio-factory models are not yet approved for clinical use. Early experience with these technologies in clinical trials foretell the potential advantages and possible limitations of remote monitoring with a variety of sustained delivery approaches.</p><p><strong>Conclusion: </strong>The combined use of sustained drug delivery and validated remote monitoring portends a significant change in the current nAMD treatment landscape and has the potential to reduce the injection and monitoring burden faced by patients while optimizing patient outcomes.</p>","PeriodicalId":7568,"journal":{"name":"American Journal of Ophthalmology","volume":null,"pages":null},"PeriodicalIF":4.1000,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ajo.2024.10.031","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: To provide a perspective on the management of neovascular age-related macular degeneration (nAMD) patients using a combination of sustained drug delivery strategies and remote monitoring technology.
Design: Evidence-based perspective METHODS: Review of the literature and experience of the author RESULTS: Currently there are many ongoing research efforts in the retina field directed at both safe, effective sustained drug delivery and validated remote monitoring. At present, the Port Delivery System with ranibizumab and the Home OCT are FDA approved and available for use by clinicians. A review of available data and a case example demonstrate the potential for these combined technologies to reduce both the injection burden and the monitoring burden currently experienced by nAMD patients. Other sustained drug delivery strategies such as tyrorinse kinase inhibitor delivery systems and viral vector mediated anti-VEGF intraocular bio-factory models are not yet approved for clinical use. Early experience with these technologies in clinical trials foretell the potential advantages and possible limitations of remote monitoring with a variety of sustained delivery approaches.
Conclusion: The combined use of sustained drug delivery and validated remote monitoring portends a significant change in the current nAMD treatment landscape and has the potential to reduce the injection and monitoring burden faced by patients while optimizing patient outcomes.
期刊介绍：
The American Journal of Ophthalmology is a peer-reviewed, scientific publication that welcomes the submission of original, previously unpublished manuscripts directed to ophthalmologists and visual science specialists describing clinical investigations, clinical observations, and clinically relevant laboratory investigations. Published monthly since 1884, the full text of the American Journal of Ophthalmology and supplementary material are also presented online at www.AJO.com and on ScienceDirect.
The American Journal of Ophthalmology publishes Full-Length Articles, Perspectives, Editorials, Correspondences, Books Reports and Announcements. Brief Reports and Case Reports are no longer published. We recommend submitting Brief Reports and Case Reports to our companion publication, the American Journal of Ophthalmology Case Reports.
Manuscripts are accepted with the understanding that they have not been and will not be published elsewhere substantially in any format, and that there are no ethical problems with the content or data collection. Authors may be requested to produce the data upon which the manuscript is based and to answer expeditiously any questions about the manuscript or its authors.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
